KLOW Blend is studied to better understand how collagen signaling, vascular repair, cell migration, and inflammatory pathways interact across four complementary mechanisms of tissue regeneration.

KLOW Blend brings together four peptides that have each been independently studied across regenerative biology, inflammatory pathway, and extracellular matrix research — and each operates through a mechanistically distinct signaling route.

GHK-Cu, the naturally occurring copper tripeptide first isolated from human plasma by Pickart in 1973, is studied for copper-dependent collagen synthesis signaling, MMP/TIMP matrix remodeling balance, and keratinocyte migration activity in skin and connective tissue preparations. BPC-157, a synthetic pentadecapeptide, contributes VEGF-dependent angiogenic signaling through VEGFR2 and FAK phosphorylation pathways. TB-500, the synthetic Thymosin Beta-4 analog, adds VEGF-independent vascular signaling via integrin αvβ3 and Akt-eNOS activation, alongside actin-mediated cell migration facilitation.

KPV — the fourth and newest addition to this formulation — is a tripeptide derived from the C-terminal sequence of α-MSH. Its primary research interest lies in its ability to enter cells via PepT1, a peptide transporter expressed in intestinal epithelial, immune, and mucosal cell preparations, where it directly inhibits NF-κB nuclear translocation and downstream pro-inflammatory cytokine expression.

KLOW Blend addresses inflammatory signaling through two separate pathway entry points simultaneously.

• CAS Number: GHK-Cu: 49557-75-7, BPC-157: 137525-51-0, TB-500: 77591-33-4, KPV: 66172-75-6
• Molecular Weight: GHK-Cu: 403.92 Da, BPC-157: 1419.53 Da, TB-500: 4963.44 Da, KPV: 358.44 Da
• Purity: ≥99%
• Also Known As: BPC-157: Body Protection Compound 157, PL-10, Bepecin TB-500: Thymosin Beta-4, Tβ4, TB4 KPV: Lys-Pro-Val, α-MSH C-terminal tripeptide KLOW Blend (proprietary combination designation)
• Chemical Formula: GHK-Cu: C₁₄H₂₃CuN₆O₄, BPC-157: C₆₂H₉₈N₁₆O₂₂, TB-500: C₂₁₂H₃₅₀N₅₆O₇₈S, KPV: C₁₆H₃₀N₄O₄

In cell-based and preclinical models, KLOW Blend’s four components engage complementary signaling pathways across tissue repair, vascular remodeling, matrix biology, and inflammatory cascade modulation.

KPV adds a fourth and intracellularly targeted anti-inflammatory mechanism. Transported into cells via PepT1, KPV directly inhibits IκB kinase activity and prevents NF-κB nuclear translocation in immune and epithelial cell preparations — suppressing downstream pro-inflammatory cytokine expression from within the cell rather than at the receptor surface. This intracellular entry route is mechanistically distinct from TB-500’s extracellular inflammatory modulation, meaning KLOW Blend targets NF-κB pathway activity at two separate points in the signaling cascade simultaneously.

• Multi-Mechanism Tissue Repair Modeling
• Dual NF-κB Pathway Inhibition Studies
• Collagen Synthesis and ECM Remodeling
• PepT1-Mediated Intracellular Signaling
• Dual-Mechanism Angiogenesis Research
• Mucosal and Epithelial Inflammation Models
• Combination Pharmacology and Pathway Attribution